Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for NovaBay Pharmaceuticals (NBY) over the last 16 years, with Q3 2025 value amounting to -$1.8 million.

  • NovaBay Pharmaceuticals' Free Cash Flow rose 2465.19% to -$1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.5 million, marking a year-over-year increase of 1568.42%. This contributed to the annual value of -$5.2 million for FY2024, which is 2123.83% down from last year.
  • Latest data reveals that NovaBay Pharmaceuticals reported Free Cash Flow of -$1.8 million as of Q3 2025, which was up 2465.19% from -$3.0 million recorded in Q2 2025.
  • In the past 5 years, NovaBay Pharmaceuticals' Free Cash Flow ranged from a high of $634000.0 in Q4 2024 and a low of -$4.3 million during Q4 2021
  • Over the past 5 years, NovaBay Pharmaceuticals' median Free Cash Flow value was -$1.7 million (recorded in 2022), while the average stood at -$1.7 million.
  • Examining YoY changes over the last 5 years, NovaBay Pharmaceuticals' Free Cash Flow showed a top increase of 18744.83% in 2024 and a maximum decrease of 27743.43% in 2024.
  • Over the past 5 years, NovaBay Pharmaceuticals' Free Cash Flow (Quarter) stood at -$4.3 million in 2021, then soared by 72.05% to -$1.2 million in 2022, then soared by 40.03% to -$725000.0 in 2023, then surged by 187.45% to $634000.0 in 2024, then crashed by 390.22% to -$1.8 million in 2025.
  • Its Free Cash Flow was -$1.8 million in Q3 2025, compared to -$3.0 million in Q2 2025 and -$1.3 million in Q1 2025.